Trial intelligence / Profile preview

Velcade in Pretreated MALT Lymphoma

NCT00210392Phase 2Terminated

Sponsor
International Extranodal Lymphoma Study Group
Start
Jul 2005
Primary completion
Nov 2007
Modality
Small Molecules, Modified Peptides
Countries
1
01

Overview

A Phase 2 trial of bortezomib in extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT), sponsored by International Extranodal Lymphoma Study Group. Started Jul 2005; status: terminated.

02

Drugs

bortezomib
03

Conditions

extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT)

Beyond the preview

Go deeper on NCT00210392.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NCT00210392.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call